{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T09:30:46Z","timestamp":1750411846716,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Clinician Scientist Program OrganAge and Interdisciplinary Center of Clinical Research of the Medical Faculty Jena","award":["413668513"],"award-info":[{"award-number":["413668513"]}]},{"name":"Else-Kr\u00f6ner-Fresenius-Stiftung within the Else Kr\u00f6ner Research School for Physicians \u201cAntiAge\u201d and Interdisciplinary Center of Clinical Research of the Medical Faculty Jena"},{"name":"Jena School for Ageing Medicine (JSAM) of Else-Kr\u00f6ner-Fresenius-Stiftung"},{"DOI":"10.13039\/100012957","name":"Friedrich-Schiller-Universit\u00e4t Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A relevant number of cancer patients who receive potentially neurotoxic cytostatic agents develop a chemotherapy-induced peripheral neuropathy over time. Moreover, the increasing use of immunotherapies and targeted agents leads to a raising awareness of treatment-associated peripheral neurotoxicity, e.g., axonal and demyelinating neuropathies such as Guillain\u2013Barr\u00e9-like syndromes. To date, the differentiation of these phenomena from concurrent neurological co-morbidities or (para-)neoplastic nerve affection as well as their longitudinal monitoring remain challenging. Neuromuscular ultrasound (NMUS) is an established diagnostic tool for peripheral neuropathies. Performed by specialized neurologists, it completes clinical and neurophysiological diagnostics especially in differentiation of axonal and demyelinating neuropathies. No generally approved biomarkers of treatment-induced peripheral neurotoxicity have been established so far. NMUS might significantly extend the repertoire of diagnostic and neuromonitoring methods in this growing patient group in short term. In this article, we present enlargements of the dorsal roots both in cytostatic and in immunotherapy-induced neurotoxicity for the first time. We discuss related literature regarding new integrative applications of NMUS for cancer patients by reference to two representative case studies. Moreover, we demonstrate the integration of NMUS in a diagnostic algorithm for suspected peripheral neurotoxicity independently of a certain cancer treatment regimen emphasizing the emerging potential of NMUS for clinical routine in this interdisciplinary field and prospective clinical trials.<\/jats:p>","DOI":"10.1186\/s40478-023-01685-9","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T17:09:29Z","timestamp":1701104969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of neuromuscular ultrasound in diagnostics of peripheral neuropathies induced by cytostatic agents or immunotherapies"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2070-2825","authenticated-orcid":false,"given":"Stefanie","family":"Hartinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Hammersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas A.","family":"Leistner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Lawson McLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Risse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Senft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Sch\u00fctze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianka","family":"Heiling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"M\u00e4urer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"issue":"12","key":"1685_CR1","first-page":"1361","volume":"90","author":"AA Argyriou","year":"2019","unstructured":"Argyriou AA et al (2019) Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. J Neurol Neurosurg Psychiatry 90(12):1361\u20131369","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1685_CR2","first-page":"353","volume":"145","author":"GR Sathya","year":"2017","unstructured":"Sathya GR et al (2017) F wave index: a diagnostic tool for peripheral neuropathy. Indian J Med Res 145(3):353\u2013357","journal-title":"Indian J Med Res"},{"key":"1685_CR3","volume-title":"Electromyography and neuromuscular disorders, clinical\u2013electrophysiological correlations","author":"D Preston","year":"2013","unstructured":"Preston D, Shapiro B (2013) Electromyography and neuromuscular disorders, clinical\u2013electrophysiological correlations. Elsevier, New York"},{"issue":"5","key":"1685_CR4","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/mus.26029","volume":"57","author":"JA Telleman","year":"2018","unstructured":"Telleman JA et al (2018) Nerve ultrasound in polyneuropathies. Muscle Nerve 57(5):716\u2013728","journal-title":"Muscle Nerve"},{"issue":"1","key":"1685_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clinph.2013.05.025","volume":"125","author":"HS Goedee","year":"2014","unstructured":"Goedee HS, Brekelmans GJ, Visser LH (2014) Multifocal enlargement and increased vascularization of peripheral nerves detected by sonography in CIDP: a pilot study. Clin Neurophysiol 125(1):154\u2013159","journal-title":"Clin Neurophysiol"},{"issue":"11","key":"1685_CR6","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinph.2015.01.011","volume":"126","author":"A Grimm","year":"2015","unstructured":"Grimm A et al (2015) The ultrasound pattern sum score\u2014UPSS. A new method to differentiate acute and subacute neuropathies using ultrasound of the peripheral nerves. Clin Neurophysiol 126(11):2216\u20132225","journal-title":"Clin Neurophysiol"},{"issue":"12","key":"1685_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/jcm11123374","volume":"11","author":"B Heiling","year":"2022","unstructured":"Heiling B et al (2022) Electrodiagnostic testing and nerve ultrasound of the carpal tunnel in patients with type 2 diabetes. J Clin Med 11(12):66","journal-title":"J Clin Med"},{"issue":"6","key":"1685_CR8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","volume":"29","author":"AF Hottinger","year":"2016","unstructured":"Hottinger AF (2016) Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 29(6):806\u2013812","journal-title":"Curr Opin Neurol"},{"key":"1685_CR9","first-page":"66","volume":"6","author":"N Mohn","year":"2023","unstructured":"Mohn N et al (2023) Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor-associated neurotoxicity. Cancer Med 6:66","journal-title":"Cancer Med"},{"issue":"10","key":"1685_CR10","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1007\/s00381-020-04718-z","volume":"36","author":"N Winter","year":"2020","unstructured":"Winter N et al (2020) Role of high-resolution ultrasound in detection and monitoring of peripheral nerve tumor burden in neurofibromatosis in children. Childs Nerv Syst 36(10):2427\u20132432","journal-title":"Childs Nerv Syst"},{"issue":"20","key":"1685_CR11","first-page":"354","volume":"117","author":"S Farschtschi","year":"2020","unstructured":"Farschtschi S et al (2020) The neurofibromatoses. Dtsch Arztebl Int 117(20):354\u2013360","journal-title":"Dtsch Arztebl Int"},{"issue":"7","key":"1685_CR12","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.clinph.2017.04.009","volume":"128","author":"T Kandula","year":"2017","unstructured":"Kandula T et al (2017) Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clin Neurophysiol 128(7):1166\u20131175","journal-title":"Clin Neurophysiol"},{"key":"1685_CR13","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364\u2013378","journal-title":"Eur J Pharmacol"},{"issue":"Pt 10","key":"1685_CR14","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1093\/brain\/awp219","volume":"132","author":"SB Park","year":"2009","unstructured":"Park SB et al (2009) Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 132(Pt 10):2712\u20132723","journal-title":"Brain"},{"issue":"6","key":"1685_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066830","volume":"8","author":"F Massicot","year":"2013","unstructured":"Massicot F et al (2013) P2X7 cell death receptor activation and mitochondrial impairment in oxaliplatin-induced apoptosis and neuronal injury: cellular mechanisms and in vivo approach. PLoS ONE 8(6):e66830","journal-title":"PLoS ONE"},{"issue":"12","key":"1685_CR16","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J et al (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(12):1217\u20131238","journal-title":"Ann Oncol"},{"key":"1685_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117424","volume":"424","author":"C Zivelonghi","year":"2021","unstructured":"Zivelonghi C, Zekeridou A (2021) Neurological complications of immune checkpoint inhibitor cancer immunotherapy. J Neurol Sci 424:117424","journal-title":"J Neurol Sci"},{"issue":"10","key":"1685_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","volume":"18","author":"JC Kao","year":"2018","unstructured":"Kao JC, Brickshawana A, Liewluck T (2018) Neuromuscular complications of Programmed Cell Death-1 (PD-1) inhibitors. Curr Neurol Neurosci Rep 18(10):63","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"7","key":"1685_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/jitc-2021-002890","volume":"9","author":"AC Guidon","year":"2021","unstructured":"Guidon AC et al (2021) Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer 9(7):66","journal-title":"J Immunother Cancer"},{"issue":"4","key":"1685_CR20","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1007\/s10072-022-05920-4","volume":"43","author":"M Villagran-Garcia","year":"2022","unstructured":"Villagran-Garcia M, Velasco R (2022) Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice. Neurol Sci 43(4):2339\u20132361","journal-title":"Neurol Sci"},{"issue":"4","key":"1685_CR21","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/cam4.1970","volume":"8","author":"L Guo","year":"2019","unstructured":"Guo L et al (2019) Safety and efficacy profile of cyclin-dependent kinases 4\/6 inhibitor palbociclib in cancer therapy: a meta-analysis of clinical trials. Cancer Med 8(4):1389\u20131400","journal-title":"Cancer Med"},{"issue":"18","key":"1685_CR22","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver BA (2014) How Taxol\/paclitaxel kills cancer cells. Mol Biol Cell 25(18):2677\u20132681","journal-title":"Mol Biol Cell"},{"issue":"10","key":"1685_CR23","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2165\/11207520-000000000-00000","volume":"71","author":"CM Perry","year":"2011","unstructured":"Perry CM (2011) Eribulin. Drugs 71(10):1321\u20131331","journal-title":"Drugs"},{"issue":"6","key":"1685_CR24","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s11523-021-00843-0","volume":"16","author":"ZT Al-Salama","year":"2021","unstructured":"Al-Salama ZT (2021) Durvalumab: a review in extensive-stage SCLC. Target Oncol 16(6):857\u2013864","journal-title":"Target Oncol"},{"issue":"6","key":"1685_CR25","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/mus.24238","volume":"50","author":"A Grimm","year":"2014","unstructured":"Grimm A et al (2014) Ultrasound differentiation of axonal and demyelinating neuropathies. Muscle Nerve 50(6):976\u2013983","journal-title":"Muscle Nerve"},{"key":"1685_CR26","first-page":"66","volume":"6","author":"TE Portland","year":"2023","unstructured":"Portland TE, Strowd R, Cartwright MS (2023) Pearls & Oysters: case of atypical peripheral nerve findings following paclitaxel for breast cancer. Neurology 6:66","journal-title":"Neurology"},{"issue":"6","key":"1685_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/diagnostics12061341","volume":"12","author":"A Erdmann","year":"2022","unstructured":"Erdmann A et al (2022) Nerve echogenicity in polyneuropathies of various etiologies-results of a retrospective semi-automatic analysis of high-resolution ultrasound images. Diagnostics 12(6):66","journal-title":"Diagnostics"},{"issue":"5","key":"1685_CR28","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/mus.26833","volume":"61","author":"TW Lycan","year":"2020","unstructured":"Lycan TW et al (2020) Neuromuscular ultrasound for taxane peripheral neuropathy in breast cancer. Muscle Nerve 61(5):587\u2013594","journal-title":"Muscle Nerve"},{"issue":"12","key":"1685_CR29","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1080\/17425255.2021.1842873","volume":"16","author":"P Alberti","year":"2020","unstructured":"Alberti P (2020) A review of novel biomarkers and imaging techniques for assessing the severity of chemotherapy-induced peripheral neuropathy. Expert Opin Drug Metab Toxicol 16(12):1147\u20131158","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"1685_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/jon.12557","volume":"29","author":"K Pitarokoili","year":"2019","unstructured":"Pitarokoili K et al (2019) Prospective study of the clinical, electrophysiologic, and sonographic characteristics of oxaliplatin-induced neuropathy. J Neuroimaging 29(1):133\u2013139","journal-title":"J Neuroimaging"},{"issue":"1","key":"1685_CR31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1468-1331.2012.03852.x","volume":"20","author":"C Briani","year":"2013","unstructured":"Briani C et al (2013) Ultrasound assessment of oxaliplatin-induced neuropathy and correlations with neurophysiologic findings. Eur J Neurol 20(1):188\u2013192","journal-title":"Eur J Neurol"},{"key":"1685_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103575","volume":"171","author":"S Tamburin","year":"2022","unstructured":"Tamburin S et al (2022) Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. Crit Rev Oncol Hematol 171:103575","journal-title":"Crit Rev Oncol Hematol"},{"issue":"28","key":"1685_CR33","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline update. J Clin Oncol 38(28):3325\u20133348","journal-title":"J Clin Oncol"},{"key":"1685_CR34","doi-asserted-by":"publisher","first-page":"8865054","DOI":"10.1155\/2020\/8865054","volume":"2020","author":"N Mohn","year":"2020","unstructured":"Mohn N et al (2020) Diagnosis and differential diagnosis of neurological adverse events during immune checkpoint inhibitor therapy. J Oncol 2020:8865054","journal-title":"J Oncol"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01685-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-023-01685-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01685-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T17:11:33Z","timestamp":1701105093000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-023-01685-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1685"],"URL":"https:\/\/doi.org\/10.1186\/s40478-023-01685-9","relation":{},"ISSN":["2051-5960"],"issn-type":[{"type":"electronic","value":"2051-5960"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"7 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Medical Faculty Jena (2023-2957-Daten, approved on 27th March 2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all subjects involved in the study or their legal representative.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare the following potential conflicts of interest: IM reports speaker and travel fees from Novocure, a grant from Medac. All other authors declare no conflicts of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}